(ATDN) Two Studies for KS

(ATDN) Two Studies for KS

Treatment Review #17 - March 1995

Tecogalen is an angiogenesis inhibitor. Angiogenesis is thought to be the process by which KS lesions grow. A drug than can inhibit, or stop this process may be able to control the KS. To participate in this trial, you must be HIV+ and have KS with 10 or more skin lesions. There is no T4 cell count requirement. You cannot have taken experimental treatments within 4 weeks of starting the study. You cannot have been on any anti-KS therapy for at least 3 weeks or have any opportunistic infection other than KS within 4 weeks prior to starting treatment. Another study is using IL-2. In a normal functioning immune system, IL-2 is a chemical that prompts special immune system cells to destroy diseased cells. IL-2 may help the immune system fight HIV and KS. An IL-2 study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. To participate in this study, you must be 18 years or older, male or female, HIV+, and have KS. Your T4 cell count must be over 200.

950301
ATR01712

Always watch for outdated information. This article first appeard in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1995 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1995. AEGIS.